RxDoctor Payments Data

Urszula Salita, MD

Family Medicine · Brooklyn, NYNPI 1508957770

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 97 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$859
  • Lilly USA, LLC$385
  • Boehringer Ingelheim$244
  • Exact Sciences$197
  • GSK$89
  • Kowa Pharmaceuticals America, Inc.$70
  • plus $273 from 10 others

What the payments were for

  • Food & beverage$2,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,831
Medicare patients
72
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate57$67,847
EliquisApixaban31$46,726
TrulicityDulaglutide23$31,380
JardianceEmpagliflozin19$26,573
XareltoRivaroxaban29$24,164
FarxigaDapagliflozin Propanediol16$22,162
JanumetSitagliptin Phos/Metformin Hcl15$15,424
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,550
Albuterol Sulfate HfaAlbuterol Sulfate88$2,783
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide150$2,572
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,475
Diltiazem 12hr ErDiltiazem Hcl13$2,349
Metoprolol Succinate173$2,110
Atorvastatin Calcium282$1,924
Levothyroxine Sodium131$1,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$46,72631 claims
Lilly USA, LLCTrulicity$385$31,38023 claims
AstraZenecaFarxiga, Breztri Aerosphere$859$29,71228 claims
Boehringer IngelheimJardiance$244$26,57319 claims
Johnson & JohnsonXarelto$20$24,16429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →